Nature study reports semaglutide extends lifespan in aged female mice
Three months of treatment started at 20 months of age attenuated ageing hallmarks and outperformed matched calorie restriction on spatial memory and glucose control.
PR
By Priya Raman · Science Reporter
Sep 2 03:00 ETSource: Nature
The wire
- 01In Nature, GLP-1 receptor agonist semaglutide given to 20-month-old female C57BL/6 mice for three months improved physiological function and modulated nutrient sensors, and continued treatment extended lifespan.
- 02Authors position semaglutide as a calorie restriction mimetic, a mechanistic frame for the pleiotropic effects clinicians already see beyond weight and glucose.
- 03Findings are in female mice only, with no human longevity data; late-life dosing effects in people remain untested.
From the source
Read at nature.comLate-life semaglutide treatment slows ageing and extends lifespan in female mice
Pharmacological glucagon-like peptide-1 receptor (GLP-1R) activation reduces food intake and is an effective therapy for type 2 diabetes and obesity 1 . The use of GLP-1 medicines has revealed pleiotropic beneficial effects beyond glucose and weight control 2 , 3 , 4 , 5 , but little is known about the underlying basis of the pleiotropic effects. Here, treatment of 20-month-old female C57BL/6 mice